Evidence map›Paper›PMID 36145903›Full record

ArticlePolymers2022

Development of a Curcumin-Loaded Lecithin/Chitosan Nanoparticle Utilizing a Box-Behnken Design of Experiment: Formulation Design and Influence of Process Parameters.

Ismail A Walbi, Mohammad Zaki Ahmad, Javed Ahmad, Mohammed S Algahtani, Amer S Alali, Samar A Alsudir, Alhassan H Aodah, Hassan A Albarqi

Abstract read
In one paragraph

Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Recent Advances in Chitosan-Based Applications-A Review.Materials (Basel, Switzerland) · 2023
    Review
  7. Review
  8. Green Synthesis of Titanium Dioxide Nanoparticles UsingMolecules (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ismail A WalbiDepartment of Clinical Pharmacy, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
Mohammad Zaki AhmadDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0003-2979-8776
Javed AhmadDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0002-7025-751X
Mohammed S AlgahtaniDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0003-0339-153X
Amer S AlaliDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kkharj 11942, Saudi Arabia.ORCID 0000-0003-2057-7918
Samar A AlsudirNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
Alhassan H AodahNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.ORCID 0000-0001-5947-986X
Hassan A AlbarqiDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.

Funding

The ministry of education and the deanship of scientific research - Najran University NU/MID/17/074
6 · The paper itself

Abstract

Curcumin (CUR) has impressive pharmacologic properties, including cardioprotective, neuroprotective, antimicrobial, and anticancer activity. However, the pharmaceutical application of CUR is limited due to its poor aqueous solubility and low bioavailability. The development of novel formulations has attracted considerable attention to the idea of applying nanobiotechnology to improve the therapeutic efficacy of these challenging compounds. In this study, CUR-loaded lecithin−chitosan nanoparticles (CUR/LCSNPs) were developed and optimized by the concentration of chitosan, lecithin, and stirring speed by a 3-factorial Box-Behnken statistical design, resulting in an optimal concentration of chitosan (A) and lecithin (B) with a 1200 rpm stirring speed (C), with applied constraints of minimal average particle size (Y1), optimal zeta potential (Y2), and maximum entrapment efficiency (%EE) (Y3). The mean particle size of the checkpoint formulation ranged from 136.44 ± 1.74 nm to 267.94 ± 3.72, with a zeta potential of 18.5 ± 1.39 mV to 36.8 ± 3.24 mV and %EE of 69.84 ± 1.51% to 78.50 ± 2.11%. The mean particle size, zeta potential, %EE, and % cumulative drug release from the optimized formulation were 138.43 ± 2.09 nm, +18.98 ± 0.72 mV, 77.39 ± 1.70%, and 86.18 ± 1.5%, respectively. In vitro drug release followed the Korsmeyer−Peppas model with Fickian diffusion (n < 0.45). The optimized technique has proven successful, resulting in a nanoformulation that can be used for the high loading and controlled release of lipophilic drugs.

Indexed as

3-factorial Box-Behnken statistical designchitosancurcuminlecithinnanoparticlesstirring speed

Identifiers

PMID36145903
PMCPMC9505816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.